San Diego-based Acutus Medical, a device maker focused on diagnosing and treating irregular heartbeats, announced it has closed a $75 million Series C round of financing.
The company’s AcQMap technology provides a 3-D, high-resolution image of the heart’s interior and maps its electrical activity. A sensor-laden “basket” catheter is threaded through a major blood vessel into the heart, providing the computerized map.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The AcQMap allows an electro-physiologist to interpret if treatment is effective by using the technology to get a new map of the heart every hour following bursts of radio energy.
The all-equity financing round included new investors Deerfield Management Company, Xeraya Capital and an undisclosed strategic investor. Previous investors Advent Life Sciences, OrbiMed and GE Ventures also participated.
The round will be used to move forward with approval and development in Europe. As Xconomy reported, the company plans to have a commercial launch there later this year, and plans to seek regulatory approval in the United States in early 2017.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
ACM001 AcutsDipole wDisclaimer from Acutus Medical on Vimeo.
